Objective: Patients receiving cancer treatments commonly experience haematological
adverse effects (AEs) related to chemotherapy or molecularly targeted therapies, which may …

Therapy with erythropoiesis-stimulating agents (ESAs) is associated with well-documented
benefits to anemic cancer patients undergoing chemotherapy, most importantly a reduction …

Background and objective: While head-to-head clinical trials demonstrate pegfilgrastim to be
as efficacious as filgrastim in reducing chemotherapy-induced neutropenia, these studies …

OBJECTIVE: Anemia is a common hematological disorder characterized by reduced
hemoglobin concentrations. Despite information on prevalence and associated outcomes …

The definition of anemia is controversial and varies with the sex, age, and ethnicity of the
patient. Anemia afflicts half of hospitalized patients and most elderly hospitalized patients …

Background: Anemia in chronic illness is associated with increased healthcare resource
utilization (HRU) and costs. In COPD, it occurs frequently and influences both clinical and …

Background Little is known about cost implications of anemia and its association with
mortality in chronic obstructive pulmonary disease (COPD). This claims analysis addresses …

Purpose. The purpose of this study was to ascertain the prevalence and factors associated
with anemia (hemoglobin [Hb] 12 g/dL) in breast cancer patients undergoing chemotherapy …

Background Most non-oncologic clinical practice guidelines recommend restrictive
allogeneic blood transfusion practices; however, there is a lack of consensus regarding the …

BACKGROUND: Phase 3 clinical trials performed primarily outside the US demonstrate that
intravesical instillation of chemotherapy immediately after transurethral resection of the …